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     Abstract: 
Aims: The SMART CRT study will assess the efficacy of an AV optimization algorithm to improve 
reverse remodeling among patients undergoing cardiac resynchronization therapy in the presence of 
interventricular electrical delay.   
Methods and Results:  The SMART CRT study is a global, multi-center, prospective, randomized 
study of patients undergoing cardiac resynchronization therapy (CRT) implantation. The primary 
endpoint of this trial is response rate to CRT, defined as decrease in left ventricular end systolic 
volume (LVESV) ≥ 15% at 6 months compared to pre-implant baseline. Additional prespecified 
analyses are: a) clinical composite endpoint combining all-cause mortality, heart failure events, 
NYHA class and Quality of Life (using a patient global assessment instrument), b) the individual 
components of the clinical composite endpoint, c) 6-minute walk distance, d) Kansas City 
Cardiomyopathy Questionnaire e) LVESV as a continuous variable, and f) absolute left-ventricular 
ejection fraction (LVEF). Subjects with intraventricular delay ≥ 70 msec measured between the right 
ventricular and left ventricular pacing leads will be randomized in a 1:1 ratio to have either an AV 
Delay and pacing chamber determined by SmartDelay™ or a Fixed AV Delay of 120 msec with 
biventricular pacing. Enrollment of an estimated 726 of subjects from up to 100 centers worldwide is 
planned to achieve 436 randomized subjects and 370 complete datasets required to power the primary 
endpoint. 
Conclusions: This trial will provide important data regarding the importance of AV Delay 
programming in patients with prolonged interventricular delay at the pacing sites. 
ClinicalTrials.gov Identifier: NCT03089281 
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Abbreviations: 
AVO – Atrio-ventricular optimization 
BSC – Boston Scientific Corporation 
CRT – Cardiac resynchronization therapy 
ECG – Electrocardiogram 
HF – Heart failure 
KCCQ – Kansas City Cardiomyopathy Questionnaire  
LV – Left ventricular 
LVEF – Left ventricular ejection fraction 
LVESV – Left ventricular end systolic volume 
NYHA – New York Heart Association classification. 
 
Introduction 
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Cardiac resynchronization therapy (CRT) is a well-established treatment for patients with 
symptomatic heart failure (HF), a reduced left ventricular (LV) ejection fraction (LVEF) and QRS 
prolongation. CRT has a number of beneficial effects including improvement in measures of quality 
of life, reverse LV remodeling and reductions in HF hospitalizations and mortality.
1–5
 The magnitude 
of benefit with CRT is affected by patient characteristics such as QRS duration and morphology, 
etiology of HF and gender. More recently it has been shown that procedural factors, such as LV 
pacing at sites of late electrical activation, as assessed by either the QLV or RV-LV durations, are 
associated with improved CRT response.
6–11
 
Optimizing atrio-ventricular (AV) timing was a standard part of CRT management for many 
years, but routine AV optimization (AVO) is no longer recommended based on disappointing results 
from multicenter randomized trials.
12–14 
However, retrospective analyses have shown that certain 
subgroups of patients may benefit from AVO, including those paced at sites of increased electrical 
delay.
15
 To understand better the role of AVO among such patients, the SMART CRT study was 
designed as a prospective, randomized trial among patients paced with prolonged interventricular 
delay.  
Rationale 
A post hoc analysis of the SMART-AV trial showed that increasing RV-LV duration was associated 
with greater reverse remodeling with AVO compared with nominal programming.
11
 For the analysis, 
the patient population was assessed by grouping into quartiles based on RV-LV duration. To provide 
more granularity to the data for the design of SMART CRT the splitting variable was changed to 10 
msec increments. As shown in Panel A of Figure 1, the proportion of patients with an RV-LV 
duration greater than a given cutoff value diminishes as the RV-LV duration increases (median 
duration was 70 msec). The patient population was evaluated in a similar fashion in which the 
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response rates for AVO and nominal programming were compared. As the RV-LV duration increases, 
the difference in response rates also increases (Panel B of Figure 1). The curve is nonlinear with a 
plateau area. Choosing a large cutoff value increases the effect size but also diminishes the number of 
available patients. To maximize the proportion of patients who may benefit from AVO, enrolling 
patients with an RV-LV duration near the onset of the plateau region (70 msec) was chosen. This 
value ensures that a clinically meaningful improvement in response rate would be observed while 
ensuring that the cutoff value is applicable to the majority of patients. 
 
Study Hypotheses 
The primary hypothesis of SMART CRT is that among patients with prolonged inrerventricular delay 
between the RV and LV leads, CRT with AVO will result in greater reverse LV remodeling compared 
with CRT programmed at nominal settings. 
 
Study Design 
The SMART CRT study is a global, multi-center, prospective, randomized study that will enroll 
subjects who intend to undergo de novo implantation of a CRT System (Boston Scientific, 
Marlborough, MA) or upgrade from a preexisting single or dual chamber device. Only patients with at 
least one RV-LV duration > 70 msec between programmable RV lead and LV pacing configuration, 
as measured automatically from the pulse generator, will be randomized. An acceptable pacing 
configuration is one with a pacing threshold ≤ 4.5 V at a pulse width of 0.5 msec and no 
diaphragmatic stimulation within 3 V above the pacing threshold. If multiple vectors meet the 
acceptable pacing criteria, the investigator will select a vector with an RV-LV delay within 10 msec 
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of the longest measured delay. In cases where there is no acceptable pacing configuation that meets 
randomization, the right or left ventricular lead can be repositioned at the discretion of the implanting 
physican; otherwise, the patient will be exited from the protocol. Subjects will be randomized in a 1:1 
ratio to have either an AV Delay and pacing chamber determined by SmartDelay™ or a Fixed AV 
Delay of 120 msec with biventricular pacing. Of note, multisite pacing is not allowed in the protocol. 
Randomized subjects will be followed semi-annually for a minimum of 540 days ± 60 days window 
(i.e., 18 months) post implant. Figure 2 is a flow chart which describes the proposed study plan from 
first enrollment to study closure. All subjects will receive a de novo quadripolar Boston Scientific 
Cardiac Resynchronization Therapy Defibrillator (CRT-D) in conjunction with an ACUITY X4 LV 
lead. Lead locations will be at the discretion of the implanting physician. 
Study Population 
The study population consists of patients with a CRT indication scheduled for either de novo 
implantation or upgrade from single or dual chamber device to a CRT-D. Of note, given that multiple 
geographies were included in this trial it was decided to use as uniform as possible an inclusion 
criteria rather than indidiual guidelines of the various regions. 
The inclusion and exclusion criteria are further described in detail within Tables 1 and 2, respectively. 
Study Endpoints 
The primary endopoint of this trial is proportion of patients with a positive response to CRT. 
CRT response is defined as a decrease in left ventricular end systolic volume (LVESV) ≥ 15% at 6 
months compared to pre-implant baseline. The proportion of patients responding to CRT will be 
compared between the randomized groups. In addition to the formal endpoint hypotheses, 
comparisons between groups for pre-specified analyses include, but are not limited to: a) clinical 
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composite endpoint combining all-cause mortality, heart failure events, NYHA class and Quality of 
Life (using a patient global assessment instrument), b) the individual components of the clinical 
composite endpoint, c) 6-minute walk distance, d) Kansas City Cardiomyopathy Questionnaire 
(KCCQ), e) LVESV as a continuous variable, and f) LVEF. 
Trial Oversight 
The study protocol was developed with a steering committee consisting of 8 physicians and a patient 
advocate. The local ethics committees of all participating sites are required to approve the study 
protocol. Central and onsite monitoring, data review and safety oversight will be provided by the 
sponsor, Boston Scientific (Marlborough, MA, USA). Echocardiograms will be interpreted by a 
blinded core laboratory. All heart failure events and deaths will be reviewed by an independent 
clinical event committee.   
 
Power Calculations 
For the primary endpoint difference in response rates between the group with a fixed AV Delay 
(120ms) and AV Delay as specified by SmartDelay the sample size is powered to obtain a 90% 
confidence level with a one-sided alpha of 2.5%. It is expected that 60% of enrolled patients will have 
an RV-LV-interval of ≥ 70 msec and undergo randomization. Attrition after randomization is 
expected to be 15%. Under those assumptions, an estimated 726 subjects will be enrolled to achieve 
436 randomized subjects and 370 patients in the analysis cohort.  
 
Statistical Analyses 
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The Primary Endpoint, in addition to the additional analyses, will be evaluated using intention-to-treat 
methodology, in which subjects with complete datasets are evaluated according to their randomized 
treatment groups. The Primary Endpoint will be evaluated using a chi-square test with a one-sided 
significance level of 2.5%, comparing the proportion of responders in the SmartDelay randomized 
group to the Fixed AV Delay randomized group. The following sensitivity analyses for the Primary 
Endpoint will be performed: intention-to-treat with missing endpoint data imputed via multiple 
imputation, on-treatment in which subjects are analyzed according treatment received and per 
protocol including only subjects programmed to their randomized assignment are included.  
The clinical composite endpoint will be assessed utilizing a Cochran-Armitage test for trend.  
Cochran–Mantel–Haenszel tests will be used to evaluate NYHA classification and patient global 
assessment. The continuous outcomes of 6-minute walk distance, KCCQ, LVESV and LVEF will be 
tested using a two-sample t-test. The time-to-event analyses of all-cause mortality and heart failure 
events will be evaluated using a log-rank test; data from any subjects who are event-free will be right 
censored on the final date of study participation.   
Subgroup analyses for the Primary Endpoint will be performed by testing the interaction between the 
subgroup and randomized group utilizing a logistic regression model. Subgroup analyses will be 
performed on the following characteristics: age, gender, ischemic etiology, conduction disorder, QRS 
duration, LV lead location, baseline NYHA classification and SmartDelay recommended 
programming (LV only vs. biventricular pacing, and AV Delay equal to 120±20 msec vs. all others). 
Multivariable logistic regression modeling will also be performed using these characteristics. 
An interim sample size re-estimation will be performed after at least half of the required 6 month 
datasets (N = 185) have been completed and reviewed by the core lab. The pooled and blinded 
response rate across both groups will be assessed in this interim sample size re-assessment cohort. 
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The observed rate will be weighted by the number of patients in each group and compared to the 
assumed weighted rate. If the observed rate is less than the assumed rate, the number of patients 
required for randomization will be increased accordingly, up to a maximum of 456 randomized 
subjects. The treatment effect will not be calculated, thereby maintaining the blind.   
Discussion 
Despite early enthusiasm for AV optimization, primarily using echocardiographic techniques, 
current consensus documents and guidelines do not recommend routine optimization based on the 
results of prospective, multicenter trials.
16,17
 As such, routine AVO has fallen out of favor. However, 
analyses of the SMART-AV trial showed that the electrogram based algorithm (SmartDelay) was 
more effective among patients with the LV lead at sites with a long left ventricular (i.e. QLV)
15
or 
interventricular (RV-LV) delay.
11
 The present trial is designed to confirm these findings prospectively 
by only randomizing patients with a prolonged RV-LV duration at implant. This would support the 
hypothesis that AVO is most effective among patients more likely to respond to CRT rather than the 
initial hope of AVO to “convert” non-responders to responders.  
The Adaptive CRT trial was another randomized trial which showed no benefit of AVO for 
the whole CRT cohort,
13
 but a subgroup was identified with LBBB and normal PR interval that was 
associated with an improved response.
18
 The AdaptResponse trial is a prospective study designed to 
validate this finding..
19
 There are some similarities between these algorithms as both are designed to 
promote fusion of intrinsic conduction to produce more synchronous LV activation including LV only 
pacing rather than choosing AV delays to optimize LV filling. Since LBBB patients have longer RV-
LV times,
10
 SMART CRT and AdaptResponse may evaluate a common mechanistic hypothesis that 
AVO that promotes electrical resynchronization is of value primarily among patients with electrical 
delay.  
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There has been much interest in reducing the purported non-responder rate to CRT. Although 
there is no consensus on the definition of response to this therapy it is clear that optimizing outcomes 
is an important goal. In this regard, certain clinical factors such as etiology of HF, gender and ECG 
characteristics including QRS duration and morphology affect CRT response. More recently, the role 
of targeting LV pacing to areas of late mechanical or electrical delay has also been shown to impact 
CRT response. The SMART CRT trial will further add to our understanding of strategies to optimize 
CRT outcomes if the results show a benefit of combining AVO with pacing at site of prolonged 
interventricular conduction delay. 
 In summary, SMART CRT is a prospective, randomized study that will be the first trial to 
evaluate the SmartDelay algorithm in patients with interventricular conduction delay using a 
quadripolar left ventricular transvenous lead. At present there are no multicenter, randomized, blinded 
trials showing the benefit of AVO for CRT so this study will potentially establish the benefit of 
routine AVO in a subset of CRT patients.  
Word Count (manuscript text, not including abstract, acknowledgements and disclosures. Maximum 
2500 words, 20 references, 5 figures or tables): 2120 
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Figure Legends 
Figure 1: Justification for Interventricular Delay Cut-off  
Panel A) Percent of CRT population with delay greater than RV-LV cutoffs, the median value 
was 70 msec.  
Panel B) The difference in CRT response between the patients in the SmartDelay and the 
Fixed delay (at 120ms) cohorts by RV-LV cutoff. Cutoffs represent RV-LV durations equal 
to or longer than the specified cutoff value.   
Data obtained from the SMART-AV Trial. 
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Figure 2:  Study Design Flow Chart 
Eligible patients (RV-LV duration ≥ 70 msec) will be randomized in the post-implant period. 
Response rates (proportion of patients with ≥ 15% decrease in LVESV from pre-implant 
echocardiogram) as well as Kansas City Cardiomyopathy Questionnaire (KCCQ), 6-Minute 
Hall Walk (6MW), LVESV and LVEF will be evaluated at a 6-month follow-up. 
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Table 1:  Study inclusion criteria 
 
Qualifying subjects are those with heart failure who CRT indications defined as those 
subjects who receive stable optimal pharmacologic therapy for heart failure and who meet 
any one of the following classifications: 
 Moderate to severe heart failure (NYHA Class III-IV) with LVEF ≤ 35% and QRS 
duration ≥ 120 msec 
 Mild heart failure (NYHA Class II) with LVEF ≤ 30% and LBBB with QRS 
duration ≥ 130 msec 
This indication is modified in Japan to restrict the QRS cutoff to 150 msec 
 Asymptomatic heart failure (NYHA Class I) with ischemic cardiomyopathy, LVEF 
≤ 30% and LBBB with QRS duration ≥ 130 msec  
This indication is eliminated in Japan 
Subject is age 18 years old or above, or of legal age and willing and capable to give informed 
consent specific to each country and national laws 
Subject must be indicated for a CRT-D system implant. This includes subjects who are 
indicated to receive an upgrade to a BSC quadripolar CRT-D device from a previously 
implanted device 
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Subject is willing and capable of complying with visits and procedures as defined by this 
protocol 
CRT=cardiac resynchronization therapy, LBBB=left ventricular bundle branch block, LVEF=left 
ventricular ejection fraction 
 
Table 2:  Study exclusion criteria 
 
Subjects with documented permanent complete AV block 
Subjects with permanent or chronic AF or in AF at the time of enrollment 
Subjects who have previously received cardiac resynchronization therapy with pacing in the left 
ventricle 
Subjects on the active heart transplant list or who has or is to receive a VAD 
Life expectancy shorter than 12 months due to any medical condition (e.g., cancer, uremia, liver 
failure) 
Subject with a known or suspected sensitivity to dexamethasone acetate 
Women of childbearing potential who are or plan to become pregnant during the course of the 
trial  
Subjects currently requiring dialysis 
AF=atrial fibrillation, AV=atrioventricular, VAD=ventricular assist device 
 
 
 
 
 
